RESEARCH ARTICLE

CLINICAL FEATURES AND HEMATOLOGICAL PARAMETERS IN SOME CHIKUNGUNYA PATIENTS, YEMEN

Eman Abdo Ali1,*, Khaled Saeed Ali2 and Riad Mohamed Alsubaihi3

1Pharmaceutis department, Faculty of Pharmacy, University of Aden, Aden, Yemen
2Pharmaceutical Chemistry, Faculty of Pharmacy, University of Aden, Aden, Yemen
3Internal medicine department, Faculty of Medicine, University of Aden, Aden, Yemen

*Corresponding author: Eman Abdo Ali; E-Mail: abdo.ali.eman@gamil.com

Received: 10 June 2020 / accepted: 27 June 2020 / Published online: 30 June 2020

Abstract

During march – May 2020, chikungunya (CHIK), an arboviral infection, has spread throughout the all area of Aden and Lahj governorate, infecting thousands of people.

The study investigated haematological parameters and Clinical features of CHIK virus infected patients attending outpatient clinic at Al-shafa and Algamheer medical center, Aden and Lahj, Yemen. 50 selected patients within the age of 14- 60 years were involved in the study according to the clinical features. The most common feature of the CHIKV infection was arthralgia and high fever. Other clinical manifestations reported as, headache, joint pain, redness of joints, swelling of joints vomiting and Fatigue Blood samples were collected and analyzed using Sysmex automated haematology analyzer for CBC test. Results showed the emergence of lymphopenia (15.7 ± 6.18%) , neutrophils (73.8 ± 6.98%) and the complete white blood cell (WBC) counts was 4.8 ± 1.4 $10^3$/μL in patients. The platelets (PLT) counts ranged from 92-244 $10^3$/μL (mean: 160 ± 47.4x103/μL). The hemoglobin decreased in 30 % of cases and was about (10 ± 1.2 g/dl) in children. By day 5 of illness the neutrophil and lymphocyte count had recovered to normal range, but the arthralgia and joint pain was continued for weeks. In addition of Clinical features, the neutrophils and lymphopenia was the main hematological indices of CHIK, in lack of CHIK antigen detection.

Keywords: Chikungunya, Clinical Features, Hematological Parameters.

1. Introduction

Chikungunya virus (CHIKV) is an arthropod-borne virus that belongs to the Alphavirus genus which is transmitted to human by mosquitoes (Aedes aegypti). With a risk to spread globally, it is a re-emerging virus given the expanding dissemination of its mosquito vectors [1]. It was first recognized as a human pathogen during an outbreak of debilitating arthritic disease in 1952 in present-day Tanzania, after it was isolated from the serum of an infected patient [2, 3].

Chikungunya disease is characterized by vast majority of symptoms including an acute illness notable for rapid onset of fever, incapacitating polyarthralgia and arthritis, rash, myalgia, headache, and polyarthralgia which is sometimes associated with rash. These symptoms intolerable usually resolve within weeks, but may last for months [4].

The Acute CHIKV disease symptomatically resembles dengue fever, and retrospective case reports suggest that CHIKV outbreaks occurred as early as 1779 but were inaccurately attributed to dengue virus. Dengue and chikungunya are both vector-borne diseases found mostly in the tropical regions of Africa and Asia for decades. However, unlike dengue, a distinguishing feature of CHIKV disease is a recurring musculoskeletal disease primarily affecting the peripheral joints that can persist for months to years after acute infection [5].

There are many factors that influence the geographical spread of both viruses, including vector distribution (both are spread by Aedes mosquitoes), human travel, urbanization, and climatic changes. Now, these two diseases can be found in many countries and challenge many clinicians because different clinical management is required for both of them even though their manifestations can be similar [6].
In some cases, Chikungunya is asymptomatic – where people do not experience any symptoms. Those who do experience symptoms usually remain ill for 3-12 days after being bitten by an infected mosquito. Symptoms include sudden fever, severe muscle, joint pain, headache, fatigue, nausea, vomiting, and a rash. Although most patients fully recover, chronic joint pain may last for several weeks or months. Other persistent problems may include eye, gastrointestinal, neurological, and heart complications. People with chronic health conditions, a weakened immune system, infants, and the elderly are at a higher risk of developing infection complications. Chikungunya is rarely fatal and its treatment includes supportive care of symptoms. However, there is no antiviral treatment available [4]. The general laboratory diagnosis of Chikungunya often reveals lymphopenia, neutrophils and thrombocytopenia, an elevated creatinine, and elevated hepatic transaminases [7, 8, 9].

An outbreak of CHIKV fever was poorly documented in Eastern Mediterranean Region of the World Health Organization (EMRO/WHO). Evidence of CHIKV in the region came from a serological survey done in 1983 in Pakistan and in 2005 from Sudan. In Yemen, the CHIKV was first confirmed in Al-Hodeida governorate in early 2011 with approximately 15,000 cases including 104 deaths, and in 2012 was reported in the first outbreak of Chikungunya fever in Southern Yemen [10, 11].

2. Materials and Methods

Among the suspected Chikungunya suffering disease cases, who diagnosed in Al-shafa medical center (Aden) and Al-Gamahir medical center (Laajh), Yemen during April- May 2020, 50 positive cases were selected (14-60 years age). Haematological parameters were studied in such patients, 3 ml of blood was drawn in day 2 of illness and in day 5 from some patients (n= 5). The blood was collected into EDTA tubes and the blood count (CBC) was evaluated three times for the selected patients, using Sysmex automated haematology analyzer.

3. Statistical analysis

The resultant values were subjected to descriptive statistics and presented as mean ± standard deviation was using Microsoft Excel 2010.

4. Result and Discussion

4.1. Symptoms and clinical features

The symptoms of patients infected with CHIKV are presented in (table 1). Arthralgia and high fever (about temperature: 38-39°C) were the most common features of the CHIKV infection was, which found to be present in all selected patients. The arthralgic pain and continuous fever were more frequently reported during the first 2 days of infection in the infected persons. In adult patients (25-60 years) were suffering myalgia accompanied by arthralgia after 3 days of infection (table 1). The previously published reports have indicated that the combination of fever and severe arthralgia (present in more than 95% of cases) [12, 13]. Other clinical manifestations reported as, headache, joint pain, redness of joints, swelling of joints, vomiting and fatigue for 3 to 5 days. In children reported rash on face, hands and legs. Several studies reported that, the fever lasts from several days up to a week is about 76-100 % of symptomatic patients, it can be continuous or intermittent with mild fever [14, 15, 16, 17, 18]. The headache, muscular pain, and joint pain of both upper and lower limbs were reported in previous studies associated by chikungunya infection [19, 12].

Table 1: Symptoms of patients with Chikungunya infection

| symptoms        | Adult (25-60 yrs) | Children (14-22 yrs) |
|-----------------|------------------|----------------------|
| N= 42           | N= 8             |
| Fever           | ++               | ++                   |
| arthralgia      | ++               | +                    |
| myalgia         | ++               |                      |
| headache        | ++               | ++                   |
| joint pain      | ++               |                      |
| redness of joints | +              |                      |
| swelling of joints | ++           | ++                   |
| Vomiting        | ++               | ++                   |
| Rash            | ++               |                      |

4.2. Hematological parameters:

During the day 2 of illness, the results of CBC showed, that a change in the rate of differential WBC level. We observed the rise of neutrophil percentage and decreasing in percentage lymphocytes and MXD (monocyte, basophil and eosinophil) table (2). These results are consistent with previous studies, which indicated that the emergence of lymphopenia and neutrophils in patients who were suffering with Chikungunya in America, Asia and Africa [14].

The result of selected studied cases showed that, the complete white blood cell (WBC) counts ranged from 3 to 7.6 10³/µL (mean: 4.8 ± 1.4 10³/µL), of which neutrophil (NTP) counts ranged between 46.8–87.3% (mean: 73.8 ± 6.98%) and lymphocyte (Lymph) counts ranged between 8-28.9% % (mean: 15.7 ± 6.18%) and MXD (monocyte, basophil and eosinophil) counts ranged
between 4.8-19.1% (mean: 9.92 ± 4.5). The similar findings were reported by [21], the neutrophils increased to 76.1% and lymphocytes decreased to 10.9% compared to normal range. The platelets (PLT) counts ranged from 92-244 10^3/μL (mean: 160 ± 47.4 10^3/μL) (table 2). By day 5 of illness the neutrophil and lymphocyte count had recovered to normal range (table 3), but the arthralgia and joint pain was continued for weeks [4].

Among the studied cases, that shown a Chikungunya had significantly lower mean hemoglobin (10 ± 1.2 g/dl) in 30% of cases, especially in children and the mean of hemoglobin was 12.39 ± 1.4 g/dl in 70% cases were within the recommended ranges (table 2). Ron et al [20] has shown that the lower mean hemoglobin presented in Chikungunya infected patients. The RBC count and percentage of hematocrit (Hct) in all cases were within the recommended ranges. Previous studies [21, 22] showed, that the differences that are most apparent at presentation are neutrophilia, lymphopenia and myalgia/arthralgia which were more likely to be present in chikungunya cases, while neutropenia, lymphopenia and thrombocytopenia were more likely to be present in dengue cases.

Table 2: Hematological Parameters of Chikungunya infected patients

| Parameters | Mean ± SD | Normal Ranges |
|------------|-----------|---------------|
| WBC        | 4.8 ± 1.4 | 4-10 x10^3/μL |
| RBC        | 4.74 ± 0.64 | 3.9-6.00 x10^6/μL |
| Hb         | 12.39 ± 1.4 | 11-16 g/dl |
| Hct        | 39.3 ± 3.8 | 34-51 % |
| NTP (%)    | 73.8 ± 6.98 | 40 – 70 % |
| Lymp (%)   | 15.7 ± 6.18 | 20 – 45 % |
| MXD (%)    | 9.92 ± 4.5 | 4 – 17 % |
| PLT        | 160 ± 47.4 | 150 – 450 x10^3/μL |

Table 3: Comparison between Hematological Parameters in the Day 2 and Day 5 of illness

| Parameters | Day 2 of illness | Day 5 of illness | Normal Ranges |
|------------|------------------|------------------|---------------|
| WBC        | 6.41 ± 1.4       | 5.05 ± 1.24      | 4-10 x10^3/μL |
| RBC        | 4.62 ± 0.38      | 4.64 ± 0.6       | 3.9-6.00 x10^6/μL |
| Hb         | 12.85 ± 0.85     | 12.28 ± 0.8      | 11-16 g/dl |
| Hct        | 38 ± 3.5         | 35.42 ± 2.7      | 34-51 % |
| NTP (%)    | 76.6 ± 7.16      | 56.86 ± 5.8      | 40 – 70 % |
| Lymp (%)   | 14.23 ± 6.2      | 30.04 ± 6.14     | 20 – 45 % |
| MXD (%)    | 10.07 ± 3.84     | 13.3 ± 2.59      | 4 – 17 % |
| PLT        | 217.88 ± 52      | 296.4 ± 64.69    | 150 – 450 x10^3/μL |

Acknowledgments

The authors acknowledge the help of Mis Nawal Alkhathiri for making the Garmeraticalll correction.

References

[1] Schilte, C., et al., Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis, 2013. 7(3): p. e2137

[2] Simon, F., et al., Chikungunya virus infection. Current infectious disease reports, 2011. 13(3): p. 218

[3] Petersen, L.R. and A.M. Powers, Chikungunya: epidemiology. F1000Research, 2016.5.

[4] Da Cunha, R.V. and K.S. Trinta, Chikungunya virus: clinical aspects and treatment-A Review. Memorias do Instituto Oswaldo Cruz, 2017. 112(8): p. 523-531.
Clinical Features and Hematological Parameters in some Chikungunya Patients, Yemen

[5] Silva, L.A. and T.S. Dermody, *Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies*. The Journal of clinical investigation, 2017. 127(3): p. 737-749.

[6] Lee, V.J., et al., *Simple clinical and laboratory predictors of Chikungunya versus dengue infections in adults*. PLoS Negl Trop Dis, 2012. 6(9): p. e1786.

[7] CDC. Chikungunya information for healthcare providers. CDC Web site. Available at: http://www.cdc.gov/chikungunya/pdfs/CHIKV_Clinicians.pdf. Accessed Jul 4, 2014. (7)

[8] Staples JE, Breimein RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. *Clin Infect Dis*. 2009;49:942-8. (8)

[9] Thiberville SD, Moyen N, Dupuis-Maguiraga L, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. *Antiviral Res*. 2013;99(3):345-70.

[10] Thabet, A., et al., *Epidemiological characterization of chikungunya outbreak in Lahj Governorate, Southern Yemen*. J Community Med Health Educ, 2013. 3(247): p. 2161-0711.1000247.

[11] Mamunur Rahman Malik, Abraham Mnzava, Emad Mohareb, Alia Zayed, Abdulhakeem Al Kohlani e, Ahmed A.K. Thabet, Hassan El Bushra. Chikungunya outbreak in Al-Hudaydah, Yemen, 2011: Epidemiological characterization and key lessons learned for early detection and control, Journal of Epidemiology and Global Health (2014) 4, 203–211 (11)

[12] Saeed Anwar, Jarin Taslem Mourosi, Md. Fahim Khan, Mohammad Ohid Ullah2, Olivier M. Vanakker3, Mohammad Jakir Hosen., Chikungunya outbreak in Bangladesh (2017): Clinical and hematological findings PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0007466 February 24, 2020 (12)

[13] Vijayakumar KP, Anish TS, George B, Lawrence T, Muthukkutty SC, Ramachandran R. Clinical profile of chikungunya patients during the epidemic of 2007 in Kerala, India. Journal of global infectious diseases.2011 Jul; 3(3):221.

[14] Pan American Health Organization Preparedness and Response for Chikungunya Virus: Introduction in the Americas Washington, D.C.: PAHO, © 2011, pp161 (14)

[15] Staikowsky F, Le Roux K, Schuffenecker I, et al. Retrospective survey of Chikungunya disease in Réunion Island hospital staff. *Epidemiol Infect*. Feb 2008;136(2):196-206. (15)

[16] Taubitiz W, Cramer JP, Kapaun A, et al. Chikungunya fever in travelers: clinical presentation and course. *Clin Infect Dis*. Jul 1 2007;45(1):e1-4. (16)

[17] Sam IC, AbuBakar S. Chikungunya virus infection. *Med J Malaysia*. 2006;61(2):264-269. (17)

[18] Lakshmi V, Neeraja M, Subbalaxmi MV, et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. *Clin Infect Dis*. 2008;46(9):1436-1442. (18)

[19] Sher Bahadur Pun, Anup Bastola, Rajesh Shah, First report of Chikungunya virus infection in Nepal, *J Infect Dev Ctries* 2014; 8(6):790-792. doi:10.3855/jide.3701 (19)

[20] Ron Christian Sison, MPH, MLS(ASCP)CM, Don Peter Dator, Delos Reyes Danielle, Malaya Kevin Angelo, Albert Jason Songco, Joseph Vincent Songco, Xandro Alexi Nieto, University of Santo Tomas. Hematological Parameters and Clinical Manifestations Between Dengue and Chikungunya Patients: A Multicentered Retrospective Study,abstract. Am J Clin Pathol 2015;144:A213 (21)

[21] Vernon J. Lee, Angela Chow, Xiaohui Zheng, Luis R. Carrasco, Alex R. Cook, David C. Lye, Lee-Ching Ng, Yee-Sin Leo.2012. Simple Clinical and Laboratory Predictors of Chikungunya versus Dengue Infections in Adults, PLOS Neglected Tropical Diseases, vol. 9, issue 6, 1-9. (22)

[22] Manal Mohamed AL- Samadi 1and Khaled Saeed Ali. 2020, Evaluation of some Hematological and Serological Changes in Dengue Patients of Lahj-Yemen, Electronic Journals of University of Aden for Basic and Applied Science, 1(1): 25-29 (23).
المؤشرات السريرية والمؤشرات الدموية لبعض مرضى الشيكوجونيا، اليمن

أيمن عبده علي١، خالد سعيد علي٢، ورياض محمد الصبحي٣

الخلاصة

خلال شهر مارس – مايو 2020 انتشرت الشيكوجونيا وهي عدوى فيروسية في جميع مناطق محافظة عدن ولحج، مما أدى إصابة آلاف الأشخاص.

بحث الدراسة الظواهر السريرية والمؤشرات الدموية للمرضى المصابين بفيروس الشيكوجونيا (Chikungunya) الذين حضروا العيادات الخارجية في مركز الشفاء (عنص) بالجمارك (لحج) الطبيين، اليمن. تم اختيار 50 مريضاً تراوح عمرهم بين 60-14 سنة مصاباً لهذه الدراسة. وفقاً للمؤشرات السريرية، كانت الظواهر الأكثر شيوعاً لمريض الشيكوجونيا هي الألم العضلي والحمى الشديدة، بالإضافة إلى الاعراض الأخرى تم الإبلاغ عنها: الصداع، حمرار الصلع، تورم الوجه، التقي و اللعاب. تم جمع عينات الدم وتحليلها باستخدام جهاز تحليل CBC. أظهرت النتائج انخفاض معدل خلايا الدم البيضاء اللالمفاوية (15.7 ± 6.18%) وزيادة في معدل خلايا الدم البيضاء المتوسطة (73.8 ± 6.98%). بلغت خلايا الدم البيضاء الكلية (310 ± 47.4) (μL) في المريض. تراوحت اعداد الصفائح الدموية بين (10 (μL) إلى (1.4 (μL) في المريض. انخفض الهيموجلوبين في 30% من الحالات وكان (1.2 g/dl) عند (10 (μL) للأنثى في اليوم الخاص من المرضى. تحدت مستويات كريات الدم المفاصلية والمعتدلة إلى المعاد الطبيعي، لكن استمرت الألمن الفعال لأسباب غير معروفة. تمت الملاحظات السريرية، زيادة خلايا الدم المفاصلة وانخفاض عدد خلايا الدم المفاضلة مؤشرات رئيسية في الدم للتحري عن مرض الشيكوجونيا في طي غاب الكشف المستمر (الإنترجي) لمرض الشيكوجونيا.

الكلمات الرئيسية: الشيكوجونيا، الظواهر السريرية، المؤشرات الدموية.